This document provides guidance on the Australian Specific Annex (ASA), which adapts the European Union Risk Management Plan (EU-RMP) to the Australian context. The ASA is required any time there are differences between how the RMP will be implemented in Australia versus what is proposed in the EU-RMP. The document outlines when an ASA is needed, provides a template for the preferred format, and describes the key sections that should be included like pharmacovigilance plans, risk minimization activities, and a summary table.
Presentation: Spotlight on prescription medicine post-market reformsTGA Australia
An overview of reform initiatives relevant to prescription medicines pharmacovigilance arising from the Review of Medicines and Medical Devices Regulation.
Presentation: Spotlight on prescription medicine post-market reformsTGA Australia
An overview of reform initiatives relevant to prescription medicines pharmacovigilance arising from the Review of Medicines and Medical Devices Regulation.
Presentation: Changes to medicine labelsTGA Australia
This presentation discusses the recent changes to medicines labelling in Australia including the history and consultation as well as the changes and features brought in with Therapeutic Goods Order No. 79.
How the TGA uses implant registry data: Experience with the Australian Orthop...TGA Australia
The recent TGA review of devices has foreshadowed a much greater role for registries in monitoring the long and intermediate term safety of new devices. This presentation provides an example of an established device registry to explore issues such as governance, funding, record linkage, reporting etc.
Presentation: Risk minimisation in the Australian contextTGA Australia
This presentation describes Risk Minimisation including general principles and the tools available for the development of Risk Minimisation Plans (RMPs)
“Regulatory writing department at Turacoz have the expertise to develop various regulatory documents such as Investigator Brochures (IBs), Protocols, Clinical Study Reports (CSRs), Common Technical Documents (CTDs) and pharmacovigilance documents such as Periodic Safety Update Reports (PSURs) and Risk Management Plans (RMPs). In these slides, we have presented an overview on Periodic safety update reports (PSURs) and also the guidelines such GVP modules and ICH E2c. We have also discussed the changes from old PSUR format to new Periodic Benefit-Risk Evaluation Report (PBRER) format.”
Online Clinical Trial Notification (CTN)TGA Australia
A brief overview of the clinical trials environment including the role of the Clinical Trial Jurisdictional Working Group and the Framework for Action (2) Provide an update on progress over the last year on key projects (3) Outline the importance of leadership and collaboration to maintain the momentum of improvements.
Presentation: Advertising therapeutic goods to consumers TGA Australia
An overview of the Therapeutic Goods Advertising Code (No. 2) 2018 (the Code) followed by a detailed walkthrough of the Code with examples to illustrate the application of the key sections.
Presentation: Pharmacovigilance: The Australian landscapeTGA Australia
Overview of current post-market monitoring regulations and practice in Australia. Focusing on changing trends and the implications for future post-market vigilance practice.
Spotlight on MMDR Further Reviews and Advertising ReformsTGA Australia
An overview of reform initiatives relating to low risk therapeutic goods and the scheduling policy framework arising from the Review of Medicines and Medical Devices Regulation.
An update on risk management plans - an evaluator's perspectiveTGA Australia
The presentation was given by the TGA at the 2014 ARCS Scientific Congress, and covers the requirements and milestones of risk management plans in Australia
Presentation: Changes to medicine labelsTGA Australia
This presentation discusses the recent changes to medicines labelling in Australia including the history and consultation as well as the changes and features brought in with Therapeutic Goods Order No. 79.
How the TGA uses implant registry data: Experience with the Australian Orthop...TGA Australia
The recent TGA review of devices has foreshadowed a much greater role for registries in monitoring the long and intermediate term safety of new devices. This presentation provides an example of an established device registry to explore issues such as governance, funding, record linkage, reporting etc.
Presentation: Risk minimisation in the Australian contextTGA Australia
This presentation describes Risk Minimisation including general principles and the tools available for the development of Risk Minimisation Plans (RMPs)
“Regulatory writing department at Turacoz have the expertise to develop various regulatory documents such as Investigator Brochures (IBs), Protocols, Clinical Study Reports (CSRs), Common Technical Documents (CTDs) and pharmacovigilance documents such as Periodic Safety Update Reports (PSURs) and Risk Management Plans (RMPs). In these slides, we have presented an overview on Periodic safety update reports (PSURs) and also the guidelines such GVP modules and ICH E2c. We have also discussed the changes from old PSUR format to new Periodic Benefit-Risk Evaluation Report (PBRER) format.”
Online Clinical Trial Notification (CTN)TGA Australia
A brief overview of the clinical trials environment including the role of the Clinical Trial Jurisdictional Working Group and the Framework for Action (2) Provide an update on progress over the last year on key projects (3) Outline the importance of leadership and collaboration to maintain the momentum of improvements.
Presentation: Advertising therapeutic goods to consumers TGA Australia
An overview of the Therapeutic Goods Advertising Code (No. 2) 2018 (the Code) followed by a detailed walkthrough of the Code with examples to illustrate the application of the key sections.
Presentation: Pharmacovigilance: The Australian landscapeTGA Australia
Overview of current post-market monitoring regulations and practice in Australia. Focusing on changing trends and the implications for future post-market vigilance practice.
Spotlight on MMDR Further Reviews and Advertising ReformsTGA Australia
An overview of reform initiatives relating to low risk therapeutic goods and the scheduling policy framework arising from the Review of Medicines and Medical Devices Regulation.
An update on risk management plans - an evaluator's perspectiveTGA Australia
The presentation was given by the TGA at the 2014 ARCS Scientific Congress, and covers the requirements and milestones of risk management plans in Australia
Pharmacovigilance - a regulator's perspectiveTGA Australia
This presentation provides an overview of the TGA's Pre-market and Post-market pharmacovigilance methods. It describes the role and content of Risk Management Plans as well as adverse event reporting and signal detection and investigation.
Australia Nutritional Supplements Market AnalysisInsights10
By 2030, it is anticipated that the Australian nutrition and supplements market will reach a value of $9.81 Bn from $4.58 Bn in 2022, growing at a CAGR of 10% during 2022-30. The market is primarily dominated by local players such as Blackmores, BioMedicals, Nutralife, and Life-Space. To get a detailed report, contact us at - info@insights10.com
Australia Nutritional Supplements Market Sample Report 2022 to 2030Insights10
By 2030, it is anticipated that the Australian nutritional and supplements market will reach a value of $9.81 Bn from $4.58 Bn in 2022, growing at a CAGR of 10% during 2022-30.
Presentation: Pharmacovigilance requirements inspected and example findingsTGA Australia
Presentations given at the TGA information sessions cover the pharmacovigilance inspection guidelines, preparing for inspections, inspection process, and close out of inspections.
Australia's healthcare diagnostic market is valued at $xx Bn in 2022 and would likely grow at a CAGR of 1.5% during 2022-2030. The Australia healthcare diagnostic market is segmented by product, end-user, and test type. The factors affecting its growth are prevalent chronic diseases, the rising geriatric population, insurance and reimbursement, and regulating bodies. To get a detailed report, contact us at - info@insights10.com
Các nguyên tắc sửa đổi về submit dữ liệu điện tử để apply cho các thuốc mới lưu hành tại Nhật Bản. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
Presentation on Pharmacovigilance basics – sponsor obligations, Complementary medicine safety – Regulatory perspective and Special considerations for complementary medicine pharmacovigilance
The challenges of regulating direct to consumer digital medical devicesTGA Australia
Presentation on digital medical devices, the role of the regulator, challenges in applying the framework to digital devices, international approaches and what is the TGA doing
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
Presentation on using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program (PVIP) update, International collaboration activities, Adverse Event Management System (AEMS)
Q and A
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
Presentation on Legislative requirements, specific risks for IMP manufacturing, manufacturing authorisations, PIC/S Guide to GMP PE009-13 and common issues
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
Presentation on the regulation of software including software as a medical device, proposed regulatory scheme for personalised medical devices, including 3D Printed Devices, proposed changes to the Essential Principles, Conformity Assessment Procedures, and the requirements for devices used in clinical trials, and clarifying the requirements for systems and procedure packs
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The Australian Specific Annex document
1. The Australian Specific Annex document
Dr Grant Pegg and Dr Stefan Baku
Medical Officers, Risk Management Plan Evaluation Section
Post-market Surveillance Branch
Therapeutic Goods Administration
ARCS and TGA RMP Workshop 12 March 2015
2. Overview
1. Overview
2. What is an ASA?
3. Why do we need an ASA?
4. When is an ASA required?
5. The ASA template as a guideline
6. Content of the ASA
7. ASA updates
8. Queries regarding the ASA
1
3. What is an ASA?
• The ASA is a document that adapts the EU-RMP to the Australian
context:
– Not a complete RMP
– Similar to country-specific annexes
• Difference to EU-RMP:
– Adapts EU-RMP to the Australian context
– Summarises certain EU-RMP sections
2
4. What is an ASA?
Different local requirements
• Local documentation (different from EU):
– Routine risk minimisation activities (PI/CMI)
– Local additional risk minimisation activities
e.g. prescriber education
• ASA
– assesses the Australian-specific risks
– ties all the local requirements together
3
5. Why do we need an ASA?
To adapt the RMP to the Australian context
Why is Australia different?
• Indigenous population
• Large Asian population
• Rurality/lack of access to specialist services
• State vs federal control over some aspects of how medicines are used
• Additional activities may require adaption to Australian systems
• Australian PI vs EU SmPC
4
6. When is an ASA required?
• Whenever there are differences between the Australian implementation of the
RMP compared to what is proposed in the RMP (this includes product
information).
That practically means…
• An ASA is required whenever an RMP is required (including RMP updates or
unsolicited submission of RMPs)
• As per the TGA’s Mandatory requirements for an effective application:
– “The RMP should be the current, unaltered EU-RMP (if available) and an
Australian Specific Annex should be included”.
5
7. When is an ASA not required?
Only if the RMP submitted will be applied in its entirety to Australia:
• No differences to the implementation and application of the RMP in the Australian
context
• Pharmacovigilance and risk minimisation activities for Australia are identical to
that detailed in the RMP
• This would usually only be in cases where an EU-RMP does not exist and an
Australian RMP has been submitted
6
8. The ASA template as a guideline
Preferred format for quick processing
• ASA template is a guideline
– Updated ASA template is the preferred format
• Updated ASA template:
– Provides clarification of existing requirements
– Was developed with stakeholders
– Will be available on the TGA website
7
9. The ASA template as a guideline
Other formats
• ASA template is a guideline
– Other formats may be acceptable, if they contain the same information
• Disadvantages of using another format:
– May be more difficult to use
– May require clarification from the TGA
– May lead to delays
– May increase the administrative burden
8
10. ASA – TGA’s preferred format
1. INTRODUCTION– scene setting, allows the reader to put this application in context
1.1 Purpose of ASA for this RMP
Briefly state which RMP this ASA relates to and how it is to be read. Are there major changes compared to the
EU-RMP which need to be stated upfront?
1.2 Registration History
A snapshot of the product’s Australian registration history thus far
Provide brief registration history of the product including previous applications and ARTG numbers
What is the nature of the current application?
What is the indication sought? Does this differ to that proposed/approved in the EU? If so, why?
1.3 History of RMPs submitted in Australia
State here whether RMPs have been previously submitted for evaluation
Are there any material changes to the RMP from when it was last evaluated? If so, they should be made clear. 9
11. ASA – TGA’s preferred format
1. INTRODUCTION
1.4 Epidemiology of the population to be treated in Australia
Provide Australian specific epidemiological information of the disease and the proposed treatment
population. Are there risk factors or a pre-disposition for disease in certain patient groups?
Will the target population generally differ from other markets, if so, why?
Is there an unmet clinical need in Australia to be considered? Are there other treatment options.
Is this medicine likely to be used in the Indigenous population? If so, are there safety related considerations
for this medicine taking into account co-morbidities, difficulty in accessing specialist services, follow-up?
If straightforward, does not need to be lengthy.
10
12. ASA – TGA’s preferred format
2. PHARMACOVIGILANCE PLAN
2.1 Pharmacovigilance Organisation in Australia
Include confirmation that the local pharmacovigilance organisation is operating in accordance with current
TGA guidelines for pharmacovigilance responsibilities of sponsors. A statement to this effect is sufficient.
2.2 Routine Pharmacovigilance activities
Describe routine activities carried out in Australia for the safety concerns identified in the EU-RMP. This
includes routine pharmacovigilance tools (eg targeted questionnaires).
If any activity in the EU-RMP is not to be implemented in Australia this should be stated including a
justification for any difference.
11
13. ASA – TGA’s preferred format
2. PHARMACOVIGILANCE PLAN
2.3 Pharmacovigilance activities for safety concerns specific to Australia (if applicable)
Are there additional safety concerns specific to Australia that are not addressed in the EU-RMP? If so, the
Australian pharmacovigilance activities proposed for these should be specified.
12
14. ASA – TGA’s preferred format
2. PHARMACOVIGILANCE PLAN
2.4 Studies Referenced in the Pharmacovigilance Plan of the RMP
State whether Australian subjects will be included in the pharmacovigilance studies detailed in the EU-RMP.
If not, describe why the study is considered to be applicable to the Australian context (in most cases it is).
Are there any RMP studies which are considered to be not relevant to the Australian context? If so, detail
these and why.
If dates for submission of study results in Australia differ from the dates proposed in the EU-RMP then a
summary table setting out the anticipated dates for their submission in Australia should be provided.
Are there additional pharmacovigilance activities to be conducted in Australia that are not outlined in the EU-
RMP? If so, these should be detailed
If there are no differences to what is proposed in the RMP and all studies are applicable in the Australian
context then this can be simply stated.
13
15. ASA – TGA’s preferred format
3. RISK MINIMISATION PLAN
• ASA provides details on risk minimisation activities undertaken in
Australia
– Routine (PI and CMI documents)
– Additional
Prescriber/patient education
Patient cards
Restricted prescribing
Registries
Evaluation of effectiveness of risk minimisation activities (may be pharmacovigilance)
14
16. ASA – TGA’s preferred format
3. RISK MINIMISATION PLAN
3.1 How risk minimisation activities will be implemented in Australia
• Detail about any additional risk minimisation activities being undertaken for Australia.
• Table detailing all planned risk minimisation measures in the Australian context and the EU-
RMP context.
– Wording pertaining to all the specified Safety Concerns and Missing Information Items in the
proposed Australian PI and CMI should be included in the table. Furthermore, the table
should identify the differences between EU and Australian risk minimisation activities (if any)
and provide a justification for each difference.
15
17. ASA – TGA’s preferred format
3. RISK MINIMISATION PLAN
Safety Concerns or
Missing Information
Risk minimisation
activities (routine and
additional) proposed in the
EU-RMP
Risk minimisation
activities (routine and
additional) proposed for
Australia
Differences between EU
and Australian activities
with justification
Safety Concern/Missing
Information Item
Routine activities
Include exact wording for EU
SmPC statements proposed
for this safety concern.
Additional activities
Include details of additional
activities to be undertaken
for this safety concern in the
EU.
Routine activities
Include exact wording for
Australian PI statements
proposed for this safety
concern.
Additional activities
Include details of additional
activities to be undertaken
for this safety concern in
Australia.
If routine and/or additional
activities differ for Australia
from that proposed in the
EU-RMP provide justification
for these differences.
16
18. ASA – TGA’s preferred format
3. RISK MINIMISATION PLAN
3.2 Potential for medication errors or other risks if applicable
• Australian information, if available, on potential for medication errors or other risks, for example: if an
extension of indication or new dosage form is proposed.
3.3 How risk minimisation activities will be evaluated in Australia.
• Provide detail about how and when evaluation of additional risk minimisation activities, including
educational activities, will be undertaken and reported to the TGA. Sponsors must demonstrate that the
measures they are using to mitigate risk are working and if not what actions they will take to ensure
effectiveness.
17
19. ASA – TGA’s preferred format
4. SUMMARY
Safety Concerns or
Missing Information
Pharmacovigilance activities
(routine and additional) proposed for
Australia
Risk minimisation activities (routine and
additional) proposed for Australia
Safety Concern/Missing
Information Item
Routine activities
e.g. Routine pharmacovigilance
Targeted questionnaires
Additional activities
Include study title/identifier
[Less detail than the previous tables;
summary only]
Routine activities
e.g. Section of the PI/CMI
Additional activities
e.g. Educational programme
[Less detail than the previous tables; summary
only]
18
20. ASA – TGA’s preferred format
OTHER SECTIONS
5. Person responsible for this RMP and contact details
• This should be the person responsible for the implementation of activities in the RMP within the sponsor
company and will usually be the Australian Contact Person for Pharmacovigilance ('the nominated contact
person').
6. References
• Provide a reference list, if required.
7. Appendices
• This section allows for flexibility of submitting additional, relevant documents as appendices to the RMP
(eg Australian-specific educational materials).
19
21. ASA – When should it be updated?
During the evaluation process:
• An updated ASA can be submitted with the sponsor’s response to the consolidated s31
questions and the RMP evaluation report.
• If an updated ASA is anticipated to be available at any other time during the evaluation process
the TGA should be notified for consideration.
• As the ASA should contain information on the PI/CMI proposed for Australia the ASA may need
updating following finalisation of the PI/CMI. If so, the updated ASA should be submitted to the
TGA.
• Any updated ASA should include a summary of changes (eg in tabulated format) from the
previous version. 20
22. ASA – When should it be updated?
Outside of the evaluation process:
• Can be submitted or requested at any time post-market (see also post-market RMP update).
• Should be submitted if there is a significant material change to the document.
• An updated ASA should be accompanied with a cover letter stating the reason for submission
(eg updated post-market due to reflect a change in the safety profile).
• For changes that have no impact on the EU RMP but impact the ASA, submission of the ASA
alone may be sufficient.
21
24. Commonly asked questions…
– How much detail is required for the epidemiology section of the ASA?
– A product is not being actively marketed yet there are outstanding additional
commitments in the ASA. There are no plans to actively market the product in
the future. Is it acceptable to remove additional commitments from the ASA?
– If there are more EU RMP updates than there are ASA updates how should the
changes be presented in the next ASA update? Does the updated EU RMP
need to contain track changes?
23
25. Commonly asked questions…
– Resourcing and scaling considerations when applying EU RMP additional risk
minimisation activities to the Australian setting. Australian population is 23
million versus EU population of 500 million.
24